图解大洋生物中报：第二季度单季净利润同比增长45.77%

Core Viewpoint - The company, Dayang Biotechnology, reported significant growth in its financial performance for the first half of 2025, with notable increases in revenue and net profit compared to the previous year [1]. Financial Performance Summary - The main revenue for the first half of 2025 reached 499 million yuan, representing a year-on-year increase of 14.2% [1]. - The net profit attributable to shareholders was 50.51 million yuan, up 60.66% year-on-year [1]. - The non-recurring net profit was 46.76 million yuan, reflecting a 60.74% increase compared to the same period last year [1]. - In Q2 2025, the company achieved a quarterly revenue of 250 million yuan, which is a 3.29% increase year-on-year [1]. - The quarterly net profit attributable to shareholders for Q2 2025 was 21.16 million yuan, showing a year-on-year growth of 45.77% [1]. - The non-recurring quarterly net profit for Q2 2025 was 17 million yuan, marking a 27.49% increase year-on-year [1]. Financial Ratios and Metrics - The company's debt ratio stood at 33.55% [1]. - Investment income was reported at -1.12 million yuan, while financial expenses amounted to -1.84 million yuan [1]. - The gross profit margin was 24.31%, which is a year-on-year increase of 27.77% [6]. - Return on assets was 4.68%, reflecting a year-on-year increase of 47.16% [6]. - Earnings per share were 0.62 yuan, up 61.05% year-on-year [6]. - The net asset per share was 12.86 yuan, with a year-on-year increase of 6.94% [6]. - Operating cash flow per share was 1.35 yuan, showing a significant increase of 235.93% year-on-year [6]. Shareholder Information - The top circulating shareholders include Yang Xingli with 4.75 million shares (6.76%), Chen Rongfang with 2.21 million shares (3.15%), and Zhejiang Dayang Biotechnology Group Co., Ltd. with 1.95 million shares (2.77%) [10].